摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | 87471-24-7

中文名称
——
中文别名
——
英文名称
(R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
英文别名
(8R)-1,4,7,8-Tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol
(R)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol化学式
CAS
87471-24-7
化学式
C6H8N4O
mdl
——
分子量
152.156
InChiKey
YFIDCUXYXQUPSM-SCSAIBSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    73.3
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • WATER-SOLUBLE CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
    申请人:Zhou Wenqiang
    公开号:US20140155336A1
    公开(公告)日:2014-06-05
    The present invention relates to a water soluble derivative of camptothecin and preparation method thereof, the derivative having a structure of formula I and being appropriate in water solubility, and having anti-cancer activity and stability of lactonic ring. The present invention also relates to a method for synthesizing the compound and medical use of the compound.
    本发明涉及一种溶性紫杉醇生物及其制备方法,所述衍生物具有式I的结构,在溶性方面适宜,并具有抗癌活性和内酯环的稳定性。本发明还涉及一种合成该化合物的方法以及该化合物的医药用途。
  • BIOCATALYTIC PRODUCTION OF NUCLEOSIDE ANALOGUES AS ACTIVE PHARMACEUTICAL INGREDIENTS
    申请人:PLASMIA BIOTECH, S.L.
    公开号:US20160076070A1
    公开(公告)日:2016-03-17
    A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.
    一种生物催化过程,用于生产活性药用成分(API)或其中间体,其中这些API或其中间体是式I的核苷类似物(NAs),并且所述的NAs作为药用抗病毒和抗癌药物具有活性,以及其中间体或前药。
  • Enzymatic production of cytosinic nucleoside analogues
    申请人:Plasmia Biotech, S.L.
    公开号:EP2883959A1
    公开(公告)日:2015-06-17
    The invention relates to a new synthesis process of cytosine nucleoside analogues by using nucleoside phosphorylase enzymes, particularly Pyrimidin Nucleoside Phosphorylases (PyNPs) or mixtures of Purine Nucleoside Phosphorylases (PNPs) and PyNPs.
    本发明涉及使用核苷酸磷酸化酶,特别是嘧啶核苷酸磷酸化酶(PyNPs)或嘧啶核苷酸磷酸化酶(PyNPs)和嘌呤核苷酸磷酸化酶(PNPs)混合物的新型合成胞嘧啶核苷类似物的过程。
  • Analogues of Coformycin and Their Use for Treating Protozoan Parasite Infections
    申请人:Furneaux Richard Hubert
    公开号:US20090227532A1
    公开(公告)日:2009-09-10
    This invention relates to compounds that are analogues of coformycin, pharmaceutical compositions containing the compounds, and methods of using the compounds for treating protozoan parasite infections, especially malaria.
    本发明涉及与可福霉素类似的化合物、包含这些化合物的制药组合物以及使用这些化合物治疗原虫寄生虫感染,尤其是疟疾的方法。
  • DEAMINATION OF ORGANOPHOSPHOROUS-NUCLEOSIDES
    申请人:Institut Univ. de Ciència i Tecnologia, S.A.
    公开号:EP3128013A1
    公开(公告)日:2017-02-08
    The invention relates to a new synthethic process for obtaining compounds of formula (I) from compounds of formula (II) by means of deaminase enzymes.
    本发明涉及一种通过脱酶从式(II)化合物中获得式(I)化合物的新合成工艺。
查看更多

同类化合物

脱氧助间型霉素 叔-丁基3-溴-8,9-二氢-5H-咪唑并[1,2-D][1,4]二氮杂卓-7(6H)-甲酸基酯 化合物RK-33 8-叔-丁基1-乙基6,7-二氢-5H-咪唑并[1,5-A][1,4]二氮杂卓-1,8(9H)-二甲酸基酯 8-(叔丁氧羰基)-6,7,8,9-四氢-5H-咪唑并[1,5-A][1,4]二氮杂-1-羧酸 6-羟基-4,5,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-8(1H)-酮 5-(8-羟基-7,8-二氢-4H-咪唑并[5,4-d][1,3]二氮杂卓-3-基)-3-(羟基甲基)环戊-3-烯-1,2-二醇 4,7-二氢咪唑并[4,5-d][1,3]二氮杂卓-8(1H)-酮 3-[(2-羟基乙氧基)甲基]-3,4,7,8-四氢咪唑并[4,5-d][1,3]二氮杂卓-8-醇 1H-咪唑并[1,5-d〕〔1,4]二氮杂(9CI) 1,4,6,7-四氢咪唑并[4,5-e][1,4]二氮杂卓-5,8-二酮 (9ci)-1H-咪唑并[1,2-a][1,4]二氮杂卓 9H-imidazo[2,1-i]purin-8-one 3-(2-chlorobenzyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one R-(-)-7-Methyl-5,6,7,8-tetrahydroimidazo<1,5-c>pyrimidin-5-on benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,64-icosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate tert-butyl (1-(1-(but-2-yn-1-yl)-4-methyl-7-oxo-6,7-dihydro-1H-imidazo[4,5-d]pyridazin-2-yl)piperidin-3-yl)carbamate 14-(7-(bromomethyl)-1H-imidazo[4,5-c]pyridin-4-yl)-14-azadispiro[5.0.57.36]pentadecane-13,15-dione cyclo-(-ImPyPyPy-(R)β-NHCbzγ-ImPyPyPy-(R)β-NHCbzγ-) benzyl N-[(23R,52R)-23-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-52-yl]carbamate 2-tert-butyldimethylsilyl-5-[(1S,2S)-2-dibenzylamino-1,4-dihydroxybutyl]-N,N-dimethylimidazole-1-sulfonamide 4-[7-(2-methyl-1H-benzimidazol-6-yl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-6,7,8,9-tetrahydropyrimido[4,5-b]indolizine-10-carbonitrile benzyl N-[(23R,52R)-52-amino-5,11,17,28,34,40,46,57-octamethyl-3,9,15,21,26,32,38,44,50,55-decaoxo-2,5,8,11,14,17,20,25,28,31,34,37,40,43,46,49,54,57,60,61,64-henicosazanonacyclo[54.2.1.14,7.110,13.116,19.127,30.133,36.139,42.145,48]hexahexaconta-1(58),4(66),6,10(65),12,16(64),18,27(63),29,33(62),35,39(61),41,45(60),47,56(59)-hexadecaen-23-yl]carbamate (8R)-3-(p-Methoxybenzyl)-8-<(tert-butyldimethylsilyl)oxy>-3,6,7,8-tetrahydroimidazo<4,5-d><1,3>diazepine 8H-Pyrazino[1,2-a]pyrimidine-8-carboxylic acid, 2-(2-aminoethyl)-4,6,7,9-tetrahydro-4-oxo-, 1,1-dimethylethyl ester 3,4,6,7-Tetrahydro-7-methyl-4-propylimidazo[4,5-e][1,4]diazepine-5,8-dione 1-methyl-1,2,3,4-tetrahydropyrido<3',2':4,5>imidazo<1,2-a>pyrimidin-2-one 5-(4H-1-piperazinyl)-11H-imidazo[1,2-c][1,3]benzodiazepine hydrobromide tert-butyl 7-(4-(benzyloxy)-2-oxopyridin-1(2H)-yl)-3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridine-2(1H)-carboxylate N-(7H-Imidazo<1,5c><1,3>diazepin-5(6H)-yliden)-N'-<2-<(5-methyl-1H-imidazol-4-yl)methylthio>ethyl>harnstoff 1,2-Dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-e][1,4]diazepin-8-one 1-benzyl-5-hydroxy-4,5,6,7-tetrahydroimidazo<4,5-e><1,4>diazepin-8(1H)-one [5-(8-Hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-pentyl]-phosphonic acid dibenzyl ester 6,7-dihydro-3-<(2-hydroxyethoxy)methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 4-chloro-8,9-dihydro-7H-pyrimido[4,5-b]azepine-6-carboxylic acid monohydrochloride 1,6-dimethyl-1,4,6,7-tetrahydro-imidazo[4,5-b]pyridin-5-one 1-Benzyl-7,8-dihydro-1H,5H-imidazo<4,5-e><1,3>diazepine-4,6-dione methyl5H,6H,7H,8H,9H-imidazo[1,2-a][1,4]diazepine-6-carboxylatedihydrochloride 3-(2,4-difluorophenyl)-7-(4-methoxybenzyl)-3,7-dihydro-2H-diimidazo[4,5-d:4',5'-f][1,3]diazepin-2-one 3-(3,5-dimethyl-cyclohexyl)-1-methyl-6-methylsulfanyl-1H-[1,3,5]triazine-2,4-dione 3-{5-[2-(2-Trimethylsilanyl-ethoxymethyl)-2H-tetrazol-5-yl]-pentyl}-3,6,7,8-tetrahydro-imidazo[4,5-d][1,3]diazepin-8-ol N-{4-[(8-cyclohexyl-2,8-diazaspiro[4.5]dec-2-yl)methyl]benzyl}-2-(1H-imidazol-4-yl)-N-(1H-imidazol-2-ylmethyl)ethanamine 4-Fluoro-3-[2-(8-hydroxy-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-3-yl)-ethyl]-benzoic acid methyl ester (8S)-3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-5-methylimidazo<4,5-d><1,3>diazepin-8-ol 6,7-dihydro-3-<<2-(p-toluoyloxy)ethoxy>methyl>imidazo<4,5-d><1,3>diazepin-8(3H)-one 3,4-dibenzyl-4,5,7,8-tetrahydro-6-hydroxy-6H-imidazo[4,5-e][1,4]diazepine-5,8-dione